Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients.

导出 LinkOut

翻译打印收藏纠错

作者： Ho-Jin,Shin ^[1] ; Dok Hyun,Yoon ^[2] ; Ho Sup,Lee ^[3] ; Sung Yong,Oh ^[4] ; Deok Hwan,Yang ^[5] ; Hye Jin,Kang ^[6] ; So Young,Chong ^[7] ; Yong,Park ^[8] ; YoungRok,Do ^[9] ; Sung-Nam,Lim ^[10] ; Jae-Cheol,Jo ^[11] ; Won Sik,Lee ^[12] ; Joo-Seop,Chung ^[13] ; Consortium for Improving Survival of Lymphoma

作者单位： Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea. ^[1] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ^[2] Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. ^[3] Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. ^[4] Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Gwangju, Korea. ^[5] Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea. ^[6] Department of Internal Medicine, Bundang Cha Hospital, Seongnam, Korea. ^[7] Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. ^[8] Department of Hematology and Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. ^[9] Department of Internal Medicine, Haeundae Baek Hospital, Busan, Korea. ^[10] Department of Internal Medicine, Ulsan University Hospital, Ulsan, Korea. ^[11] Department of Hematology and Oncology, Inje University College of Medicine, Busan Paik Hospital, Busan, Korea. ^[12] Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea. Electronic address: hemon@pusan.ac.kr. ^[13]